28. Synthetic Strategies to Access Fluorinated Azoles
Abd El-Gaber, M. K.; Djugovski, M.; Huang, T.-Y.; Adhikari, S.; Roy, S.*
European Journal of Organic Chemistry. 2025, ASAP. DOI: https://doi.org/10.1002/ejoc.202500508

27. 1,2,4-Triazole-based first-in-class non-nucleoside inhibitors of bacterial enzyme MraY
Berida, T.; Huang, T.-Y.; Weck, S.; Lutz, M.; McKee, S.; Kagerah, N.; Manning, D.; Jahan, M.; Mishra, S.; Hermann, J.; Muller, R.; Doerksen, R.; Stallings, C.; Christian Ducho, C.; Roy, S.*
ACS Bio & Med Chem Au, 2025, ASAP. DOI: https://doi.org/10.1021/acsbiomedchemau.5c00158
Non-peer-reviewed version of this article has been posted as a preprint: bioRxiv 2025. DOI: 10.1101/2025.01.30.635793

26. HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response
Slone, S.; Anthony, S. R.; Green, L. C.; Parkins , S.; Acharya, P.; Kasprovic, D. A.; Reynolds, K.; Jaggers, R. M.; Nieman, M. L.; Alam, P.; Wu, X.; Roy, S.; Aubé, J.; Xu, L.; Li, Z.; Lorenz, J. N.; Owens, A. P.; Kanisicak, O.; Tranter, M.
The FASEB Journal. 2025; 39:e70433. DOI:10.1096/fj.202400532RRR
Non-peer-reviewed version of this article has been posted as a preprint: bioRxiv 2023. DOI: https://doi.org/10.1101/2023.01.17.524420

25. Plant antibacterials: The challenges and opportunities
Berida, T.; Adekunle, Y. A.; Dada-Adegbola, H.; Kdimy, A.; Roy, S.; Sarkar, S. D.
Heliyon 2024, 10, E31145. DOI: https://doi.org/10.1016/j.heliyon.2024.e31145

24. Morpholine-mediated defluorinative cycloaddition of gem-difluoroalkenes and organic azides
Huang, T.-Y.; Djugovski, M.; Manning, D. L.; Adhikari, S.; Roy, S.*
Beilstein Journal of Organic Chemistry 2023, 19, 1545–1554. DOI: https://doi.org/10.3762/bjoc.19.111
Non-peer-reviewed version of this article has been posted as a preprint: ChemRxiv, 2023. DOI: https://doi.org/10.26434/chemrxiv-2023-w2r84

23. Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis
Berida, T.; McKee, S. R.; Chatterjee, S.; Li, W.; Pandey, P.; Tripathi, S. D.; Doerksen, R. D.; Jackson, M.; Ducho, C.; Stallings, C. L.; Roy, S.*
ACS Infectious Diseases 2023, 9, 2282–2298. DOI: https://doi.org/10.1021/acsinfecdis.3c00341
Non-peer-reviewed version of this article has been posted as a preprint: bioRxiv, 2023. DOI: https://doi.org/10.1101/2022.11.14.516356

22. The challenges and opportunities of developing small molecule inhibitors of MraY
Manning, D. L.; Huang, T.-Y.; Roy, S.*
Annual Reports in Medicinal Chemistry, Special Volume on New Approaches Towards Novel Antibacterial Agents project. 2023, 60, 2–159. Invited Review. DOI: https://doi.org/10.1016/bs.armc.2023.09.005
21. Small Molecules Targeting the RNA-Binding Protein HuR Inhibit Tumor Growth in Xenografts
Wu, X.; Ramesh, R.; Wang, J.; Zheng, Y.-G.; Armaly, A.; Wei, L.; Xing, M.; Roy, S.; Lan, L.; Gao, P.; Miao, Y.; Xu, L.; Aubé, J.
Journal of Medicinal Chemistry 2023, 66, 2032–2053. DOI: https://doi.org/10.1021/acs.jmedchem.2c01723

20. HuR-dependent expression of Wisp1 is necessary for TGF-induced cardiac myofibroblast activity
Green, L. C; Slone, S.; Anthony, S. R.; Guarnieri, A. Parkins, S.; Shearer, S. M.; Neiman, M. L.; Roy, S.; Aubé, J.; Wu, X.; Xu, L., Tranter, M.*
Journal of Molecular and Cellular Cardiology, 2022, Online ahead of print. DOI: 10.1016/j.yjmcc.2022.10.007
19. Identification of Potential Non-nucleoside MraY Inhibitors for Tuberculosis Chemotherapy from Structure-based Virtual Screening
Pandey, P.; Chatterjee, S.; Berida, Tomayo; Doerksen, R.J.; Roy, S.*
Journal of Biomolecular Structure & Dynamics, 2022, 40, 4832. DOI: 10.1080/07391102.2020.1862705
18. Optimization Rules for SARS-CoV-2 Mpro Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site
Stoddard, S. V.;* Stoddard, S. D; Oelkers, B. K.; Fitts, K.; Whalum, K.; Whalum, K.; Hemphill, A. D.; Manikonda, J.; Martinez, L. M.; Riley, E. G.; Roof, C. M.; Sarwar, N.; Thomas, D. M.; Ulmer, E.; Wallace, F. E.; Pandey, P.; Roy, S.
Viruses, 2020, 12, 942. DOI: 10.3390/v12090942
17. Targeting RNA-binding Protein HuR to Inhibit Human Breast Cancer Invasion and Metastasis
Wu, X.; Gardashova, G.; Lan, L.; Han, S.; Zhong, C.; Marquez, R.; Wood, S.; Roy, S.; Gowthaman, R.; Karanicolas, J.; Gao, P.; Dixon, D.; Welch, D.; Li, L.; Ji, M.; Aubé, J.; Xu, L.*
Communications Biology, 2020, 3, 193. DOI: 10.1038/s42003-020-0933-1
16. Fluorinated 1,2,3-Triazoles from α-Fluoronitroalkenes as Surrogates of α-Fluoroalkynes via Regioselective Cycloaddition Reactions with Organic Azides
Jana, S.; Adhikari, S.; Cox, M. R.; Roy, S.*
Chemical Communications 2020, 56, 1871. DOI: 10.1039/C9CC09216A
15. HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A
Andrade, D.; Mehta, M.; Griffith, J.; Oh, S.; Corbin, J.; Babu, A.; De, S.; Chen, A.; Zhao, Y. D.;Husain, S.; Roy, S.; Xu, L.; Aube, J.; Janknecht, R.; Gorospe, M.; Herman, T.; Ramesh, R.; Munshi, A.*
Cancers 2019, 11, 2014. doi:10.3390/cancers11122014.
14. The HuR CMLD-2 Inhibitor Exhibits Antitumor Effects via MAD2 Downregulation in Thyroid Cancer Cells
Allegri, L.; Baldan, F.*; Roy, S.; Aubé, J.; Russo, D.; Filetti, S.; Damante, G.
Scientific Reports 9, 2019, Article number: 7374.
13. Human antigen R as a therapeutic target in pathological cardiac hypertrophy
Green, L.G.; Anthony, S. R.; Slone, S.; Lanzillotta, L.; Nieman, M. L.; Wu, X.; Robbins, N,; Jones, S. M.; Roy, S.; Owens, A. P.; Aubé, J.; Xu, L.; Lorenz, J. N.; Blaxall, B. C.; Rubinstein, J.; Benoit, J. B.; Tranter, M.*
JCI Insight, 2019; 4(4):e121541.
12. Identification of Antimalarial Inhibitors Using Late-Stage Gametocytes in a Phenotypic Live/Dead Assay
Spicer, T. P.*; Gardiner, D. L.; Schoenen, F. J.; Roy, S.; Griffin, P. R.; Chase, P.; Scampavia, L.; Hodder, P.; Trenholme, K. R.
SLAS DISCOVERY: Advancing Life Sciences R&D, 2019, 24, 38–46.
11. Hexafluoroisopropanol and Acetyl Chloride Promoted Catalytic Hydroarylation with Phenols
Roy, S.; Motiwala, H. F.; Koshlap, K. M.; Aubé, J.*
European Journal of Organic Chemistry, 2018, 306–315.

10. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells
Muralidharan, R.; Mehta, M.; Ahmed, R.; Roy, S.; Xu, L.; Aubé, J.; Chen, A.; Zhao, Y.; Herman, T.; Ramesh, R.*; Munshi, A.*
Scientific Reports, 7, 2017, Article number: 9694.
Prior to Ole Miss
9. N-Phenylbenzamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore
Roy, S.; Sileikyte, J.; Neuenswander, B.; Hedrick, M. P.; Chung, T. D. Y.; Aubé, J.; Schoenen, F. J.*; Forte M. A.*; Bernardi, P.*
ChemMedChem, 2016, 11, 283–288.

8. Discovery, Synthesis, and Optimization of Diarylisoxazole-3-carboxamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore
Roy, S.; Sileikyte, J.; Schiavone, M.; Neuenswander, B.; Argenton, F.; Aubé, J.; Hedrick, M. P.; Chung, T. D. Y.; Forte M. A.; Bernardi, P.; Schoenen, F. J.
ChemMedChem, 2015, 10, 1655–1671.

7. A Practical and Scalable Synthesis of (S)- and (R)-1-(Dimethoxyphosphoryl)allyl Methyl Carbonates
Roy, S.; Sutivisedsak, N.; Hamper, B. C.; Lyss, A. M.; Spilling, C. D.
Synthesis, 2015, 47, 3669–3672.

6. Small Molecules Targeting the Mitochondrial Permeability Transition
Sileikyte, J.; Roy, S.; Porubsky, P.; Neuenswander, B.; Wang, J.; Hedrick, M.; Pinkerton, A. B.; Salaniwal, S.; Kung, P.; Mangravita-Novo, A.; Smith, L. H.; Bourdette, D. N.; Jackson, M. R.; Aubé, J; Chung, T. D. Y.; Schoenen, F. J.; Forte M. A.; Bernardi, P.
Probe Reports from the NIH Molecular Libraries Program. Submitted in April, 2014; Peer-reviewed in July, 2014.
5. Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-Amidinophenylbenzamides as Potent Inhibitors of Venezuelan Equine Encephalitis Virus
Schroeder, C. E.; Yao, Y.; Sotsky, J.; Smith, R. A.; Roy, S.; Chu, Y-K, Guo, H.; Tower, N. A.; Noah, J. W.; McKellip, S.; Sosa, M.; Ramussen, L.; Smith, L. H.; White. E. L.; Aubé, J.; Jonsson, C. B.; Chung, D.; Golden, J. E.
Journal of Medicinal Chemistry, 2014, 57, 8608–8621.

4. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV)
Chung, D.; Schroeder, C. E.; Sotsky, J.; Yao, T.; Roy, S.; Smith, R. A.; Tower, N. A.; Noah, J. A.; McKellip, S.; Sosa, M.; Rasmussen, L.; White, E. L.; Aubé, J.; Golden, J. E.
Probe Reports from the NIH Molecular Libraries Program. Submitted in December, 2012; Peer-reviewed in February, 2013.
3. An Expeditious Total Synthesis of Both Diastereomeric Lipid Dihydroxytetrahydrofurans from Notheia Anomala
Roy, S.; Spilling, C. D.
Organic Letters, 2012, 14, 2230–2233.

2. Synthesis of the C(18)-C(34) Fragment of Amphidinolide C and the C(18)-C(29) Fragment of Amphidinolide F
Roy, S.; Spilling, C. D.
Organic Letters, 2010, 12, 5326–5329.

1. A Task Specific Basic Ionic Liquid, [BmIm]OH-promoted Efficient green and One-pot Synthesis of Tetrahydrobenzo[b]pyran Derivatives
Ranu, B. C.; Banerjee, S.; Roy, S.
Indian Journal of Chemistry, 2008, 47B, 1108–1112.
Patent
5. Compounds for the Treatment of Retinitis Pigmentosa and Methods of Making and Using the Same
Roy, S.; Djugovski, M.; Huang, T.-Y.
63/510,709, provisional patent application filed on 6/28/2023.
4. Cysteine-based Peptidomimetics with Antimycobacterial Properties
Roy, S.; Berida, T.; Stallings, C. L.; Manning, D.L.; McKee, S.
US 18/604,626, US nonprovisional filed on 3/14/2024
3. Selective Agents Targeting Mycobacterium Tuberculosis
Roy, S., Berida, T.; Doerksen, R. J.; Stallings, C. L., and McKee, S.; Ducho, C. D.
PCT/US2023/061619 (2023), WO2023147571
2. Inhibitors of RNA-Binding Proteins, Compositions Thereof, and Therapeutic Uses Thereof
Aubé, J.; Roy, S.; Xu, L.; Wu, X.; Lan, L.
Patent filed on 05/01/19, Serial No. 62/841,600.
1. Small Molecule Inhibitors of the Mitochondrial Permeability Transition Pore (mtPTP)
Roy, S.; Bernardi, P.; Forte, M. A.; Schoenen, F. J.; Sileikyte, J.
PCT Int. Appl. (2016), WO 2016073633 A1 20160512.